Document Type
Article
Publication Date
12-1-2018
Publication Title
Hepatol Commun
Abstract
There are limited data on direct-acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs. We report the first published experience using SOF/VEL/VOX after liver transplantation for a DAA-experienced patient with severe hepatitis due to early recurrent GT3 HCV. The patient was treated with SOF/VEL/VOX that was extended to a total duration of 16 weeks and was intensified with ribavirin (RBV) starting at week 8 due to persistent viremia during treatment. Sustained virologic response at 12 weeks (SVR12) after treatment completion was achieved. SOF/VEL/VOX was well tolerated, and immediate drug-drug interaction (DDI) with tacrolimus (TAC) was not evident. Due to improvement in liver metabolic function with increasing TAC clearance, TAC dose adjustment was required throughout the treatment course.
Clinical Institute
Digestive Health
Department
Gastroenterology
Department
Surgery
Department
Infectious Diseases
Recommended Citation
Cardona-Gonzalez, Maria G; Goldman, Jason D; Narayan, Lawrence; Brainard, Diana M; and Kowdley, Kris V, "Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation." (2018). Articles, Abstracts, and Reports. 904.
https://digitalcommons.providence.org/publications/904
